- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02978209
Comparison of Different Concentrations of Carbamide as Moisturizers in Ichthyosis Vulgaris (Urea-IV)
October 29, 2019 updated by: University of Aarhus
Double Blinded Randomized Clinical Study of Carbamide as Moisturizer in Ichthyosis Vulgaris
A randomized double blinded clinical trial will be conducted comparing the effect of two simple basic moisturizers only different in the concentration of carbamide (urea).
The concentrations of carbamide will be tested are 0 and 7.5, respectively.
The study will be conducted as a split-body-study and will contain two arms randomized to comparing 0 and 7.5 % carbamide, respectively.
Approximately 20 patients with at least clinically verified Ichthyosis Vulgaris will be enrolled to each study arm.
The effect of the moisturizers will be assessed by clinical examination (score), patients assesment of effect and measurement of transepidermal water loss (TEWL) and other skin parameters.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aarhus, Denmark, DK-8000
- Department of Dermatology, Aarhus University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinically diagnosed with Ichthyosis Vulgaris
Exclusion Criteria:
- All other forms of Ichthyosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Only moisturizer, no carbamide
20 patients with Ichthyosis Vulgaris at age 0-80 years old.
One body half
|
|
|
Active Comparator: Moisturizer + 7,5 % carbamide
20 patients with Ichthyosis Vulgaris at age 0-80 years old.
Other body half
|
Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin dryness
Time Frame: 2-8 weeks
|
Transepidermal water loss ('TEWL) (g/m2/h)
|
2-8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Uffe Koppelhus, MD, PhD, Associate professsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2019
Primary Completion (Anticipated)
January 1, 2020
Study Completion (Anticipated)
March 31, 2020
Study Registration Dates
First Submitted
November 8, 2016
First Submitted That Met QC Criteria
November 28, 2016
First Posted (Estimate)
November 30, 2016
Study Record Updates
Last Update Posted (Actual)
November 1, 2019
Last Update Submitted That Met QC Criteria
October 29, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UFKOPAUH201601
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ichthyosis Vulgaris
-
Crown Laboratories, Inc.CompletedIchthyosis VulgarisUnited States
-
St. James's Hospital, IrelandUniversity of Dublin, Trinity College; Science Foundation IrelandRecruitingAtopic Dermatitis | Psoriasis Vulgaris | Ichthyosis VulgarisIreland
-
Kerecis Ltd.American Burn Association; BData, Inc.Enrolling by invitationPartial-thickness Burn WoundsUnited States
-
Maastricht University Medical CenterCompletedCongenital IchthyosisNetherlands
-
LEO PharmaTimber Pharmaceuticals Inc.CompletedCongenital IchthyosisUnited States, Australia
-
Northwestern UniversityViraCor LaboratoriesCompletedAtopic Dermatitis | Ichthyosis VulgarisUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedAutosomal Recessive Congenital Ichthyosis | Epidermolytic IchthyosisFrance
-
Krystal Biotech, Inc.Active, not recruitingTGM-1 Related Autosomal Recessive Congenital IchthyosisUnited States
-
Northwestern UniversityIcahn School of Medicine at Mount SinaiCompletedNetherton Syndrome | Ichthyosis | Lamellar Ichthyosis | Autosomal Recessive Congenital Ichthyosis | Congenital Ichthyosiform Erythroderma | Epidermolytic IchthyosisUnited States
-
Centre Hospitalier Universitaire de NiceCompletedLamellar IchthyosisFrance
Clinical Trials on 7.5 %
-
GlaxoSmithKlineCompletedAtherosclerosisUnited Kingdom
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.CompletedObesity | OverweightChina
-
Laval UniversityCompletedAcute Coronary Syndrome | Stable Angina | Unstable AnginaCanada
-
Universidad de GranadaCompletedHead and Neck Cancer | Head and Neck Neoplasms | XerostomiaSpain
-
Bioverativ, a Sanofi companyCompletedPurpura, Thrombocytopenic, IdiopathicUnited Kingdom, United States, Germany
-
Johann Wolfgang Goethe University HospitalPfrimmer Nutricia GmbH, Erlangen , GermanyCompletedEnd-Stage Renal DiseaseGermany
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingChemotherapy Induced Thrombocytopenia
-
Zealand PharmaProfil Institut für Stoffwechselforschung GmbHCompletedOverweight and ObesityGermany
-
AmDermaCompletedSkin Diseases | Skin Diseases, Papulosquamous | Plaque PsoriasisUnited States
-
Chia Tai Tianqing Pharmaceutical Group Nanjing...RecruitingGastroesophageal AdenocarcinomaChina